DPP4
ENSG00000197635
Target class
Enzyme
Chromosome
2
Approved drugs
13
Clinical candidates (approved and in development)
19
- Approved drugs
- 13
- Clinical candidates (approved and in development)
- 19
- Chemical probe available
- Yes
- Other names
- DPPIV
- Target name
- DPP4
- Gene name
- Dipeptidyl peptidase 4
- Gene symbol
- DPP4
- Protein name
- Dipeptidyl peptidase 4 (EC 3.4.14.5) (ADABP) (Adenosine deaminase complexing protein 2) (ADCP-2) (Dipeptidyl peptidase IV) (DPP IV) (T-cell activation antigen CD26) (TP103) (CD antigen CD26) [Cleaved into: Dipeptidyl peptidase 4 membrane form (Dipeptidyl peptidase IV membrane form); Dipeptidyl peptidase 4 soluble form (Dipeptidyl peptidase IV soluble form)]
- CD26
- ADCP2
- Gene biotype
- Protein coding
- Gene family
- CD molecules|DASH family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 37
- Highest tissue expression
- 48.83
- Tissue specificity (Gini)
- 0.669
- Tissue specificity (tau)
- 0.906
- KEGG gene identifiers
- hsa:1803
- Protein interaction confidence
- 0.860824
- Protein interaction partners
- 51
- R-HSA-381771
- R-HSA-400511
- End position
- 162074394
- Start position
- 161992244
- Chromosome
- 2
- Strand
- Reverse
- [Dipeptidyl peptidase 4 soluble form]: Secreted . Note=Detected in the serum and the seminal fluid. .
- SUBCELLULAR LOCATION: Cell membrane
- Single-pass type II membrane protein. Apical cell membrane
- Single-pass type II membrane protein. Cell projection, invadopodium membrane
- Single-pass type II membrane protein. Cell projection, lamellipodium membrane
- Single-pass type II membrane protein. Cell junction . Membrane raft . Note=Translocated to the apical membrane through the concerted action of N- and O-Glycans and its association with lipid microdomains containing cholesterol and sphingolipids (PubMed:11773049). Redistributed to membrane rafts in T-cell in an interleukin-12-dependent activation (PubMed:12676959). Its interaction with CAV1 is necessary for its translocation to membrane rafts (PubMed:17287217). Colocalized with PTPRC in membrane rafts (PubMed:12676959). Colocalized with FAP in invadopodia and lamellipodia of migratory activated endothelial cells in collagenous matrix. Colocalized with FAP on endothelial cells of capillary-like microvessels but not large vessels within invasive breast ductal carcinoma (PubMed:16651416). Colocalized with ADA at the cell junction in lymphocyte-epithelial cell adhesion (PubMed:11772392). Colocalized with IGF2R in internalized cytoplasmic vesicles adjacent to the cell surface (PubMed:10900005). .
- PubMed 10951221
- PubMed 16254193
- PubMed 10900005
- PubMed 11772392
- PubMed 8101391
- PubMed 11773049
- PubMed 16651416
- PubMed 17287217
- PubMed 12676959
- Tissue specificity (tau)
- 0.905548
- Expression inequality (Gini)
- 0.669165
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 48.83
- Prostate
- 28.25
- Small Intestine - Terminal Ileum
- 28.24
- Kidney - Cortex
- 19.71
- Adipose - Subcutaneous
- 16.67
Expression in transcripts per million
- Cells - Cultured fibroblasts48.83
- Prostate28.25
- Small Intestine - Terminal Ileum28.24
- Kidney - Cortex19.71
- Adipose - Subcutaneous16.67
- Adipose - Visceral (Omentum)12.55
- Kidney - Medulla11.61
- Lung10.73
- Spleen10.1
- Nerve - Tibial9.32
- Breast - Mammary Tissue9.21
- Minor Salivary Gland7.71
- Skin - Sun Exposed (Lower leg)7.14
- Colon - Transverse7.09
- Liver6.41
- Colon - Sigmoid5.07
- Ovary4.61
- Skin - Not Sun Exposed (Suprapubic)4.57
- Vagina3.8
- Uterus3.42
- Cervix - Endocervix3.33
- Cells - EBV-transformed lymphocytes3.29
- Adrenal Gland2.81
- Whole Blood2.38
- Cervix - Ectocervix2.18
And 29 more, listed on the interactive page.
- GO:0001666
- GO:0006508
- GO:0008284
- GO:0010716
- GO:0016486
- GO:0031295
- GO:0033632
- GO:0042110
- GO:0043542
- GO:0090024
- GO:0120116
- GO:0005576
- GO:0005765
- GO:0005886
- GO:0005925
- GO:0009986
- GO:0016020
- GO:0016324
- GO:0030027
- GO:0030139
- GO:0045121
- GO:0070062
- GO:0070161
- GO:0001618
- GO:0002020
- GO:0004252
- GO:0005102
- GO:0005515
- GO:0008236
- GO:0008239
- GO:0008240
- GO:0042802
- GO:0042803
- GO:0045499
Related records
Trials (1,129)
- 12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin
- 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
- 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy
- 30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
- A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus
- A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes
- A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes
- A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes
Drugs (28)
- Alogliptin Dipeptidyl peptidase IV inhibitor
- Alogliptin benzoate Dipeptidyl peptidase IV inhibitor
- Anagliptin Dipeptidyl peptidase IV inhibitor
- Begelomab Dipeptidyl peptidase IV inhibitor
- Bisegliptin Dipeptidyl peptidase IV inhibitor
- Carmegliptin Dipeptidyl peptidase IV inhibitor
- Carmegliptin dihydrochloride Dipeptidyl peptidase IV inhibitor
- Cofrogliptin
- DBPR-108 Dipeptidyl peptidase IV inhibitor
- Dutogliptin Dipeptidyl peptidase IV inhibitor
- Dutogliptin tartrate Dipeptidyl peptidase IV inhibitor
- Evogliptin Dipeptidyl peptidase IV inhibitor
- Gemigliptin Dipeptidyl peptidase IV inhibitor
- Gosogliptin Dipeptidyl peptidase IV inhibitor
- Linagliptin Dipeptidyl peptidase IV inhibitor
- Omarigliptin Dipeptidyl peptidase IV inhibitor
- Saxagliptin Dipeptidyl peptidase IV inhibitor
- Saxagliptin anhydrous Dipeptidyl peptidase IV inhibitor
- Saxagliptin hydrochloride Dipeptidyl peptidase IV inhibitor
- Sitagliptin Dipeptidyl peptidase IV inhibitor